Address: Insure Insights 61 Bridge Street, Kington.HR5 3DJ United Kingdom

Global Basal Insulin (Long-Acting Insulin) Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Home
  • Reports
  • Global Basal Insulin (Long-Acting Insulin) Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028
Global Basal Insulin (Long-Acting Insulin) Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

Global Basal Insulin (Long-Acting Insulin) Market Outlook 2028: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

  • Published Date: 08 May 2021
  • Report ID: HLT 00199
  • Pages:178
  • Base Year: 2019
  • Format: PDF
  • Historical Data: 2016-2019

Global Basal Insulin (Long-Acting Insulin) Market is anticipated to rise at a value CAGR of 8.36% over 2019-2028. According to a study published by Insure Insights on the Global Basal Insulin (Long-Acting Insulin) Market. Global Basal Insulin (Long-Acting Insulin) is a longer-acting form of insulin to keep blood glucose levels stable in the periods of fasting and has an advantage that dosing is given only once and thus controls the insulin level for about 24 hours and thus is considered a better than shorter-acting insulin. Less stringent regulatory condition in developing economies like, India, China, Mexico, and Peru, lower price of insulin have boosted the market growth

Top Driver: The rise in the incidences of diabetes worldwide have escalated the demand of the market

The upsurge in the incidence of diabetes around the globe, rise in population growth, and the growth in the geriatric population have primarily boosted the market growth. The rise in the prevalence of lifestyle-induced disorders like obesity, and consumption of alcohol, and growth in heredity based diabetes has escalated market revenue. The advantages of long-acting insulin over other types of insulin are attributing to the growth of the market.

Insulin Glargine in the product type segment has made the highest segmental growth in the Global Basal Insulin (Long-Acting Insulin) Market

Based on the Product Type, Insulin Glargine segment has dominated the segmental growth as they are more efficient long-acting insulin, it is taken daily at bedtime and exhibits a relatively constant glucose-lowering profile for over 24 hours. It is safe and effective and have been approved only for use for adults and children 6 years and older.

In terms of the Application, type2 diabetes segment have held obtained the most significant growth as Type 2 diabetes is more dominant in old and also in many adults; the growth in the geriatric population around the globe has further expanded the market.

North America boosts the regional market due to the rise in the occurrence of diabetes    

North America had held the highest growth in the region due to the rise in the occurrence of diabetes in the region. The increase in the geriatric population suffering from diabetes, growth in the obese population, and advances in healthcare infrastructure has boosted the regional growth of the market. The growth in the healthcare expenditure growing, product launches into the region has fostered the regional growth of North America.  The surge in government initiatives in diabetes management has further boosted the regional growth.

 Product Launches, strategic collaborations, mergers, and acquisition, are the major strategies of the competitors

The Players of the Global Basal Insulin (Long-Acting Insulin) Market is fragmented.  Product launches, collaborations, mergers, and acquisitions are strategies used by competitors for the overall growth. The key competitors of the Global Basal Insulin (Long-Acting Insulin) Market are Novo Nordisk, Sanofi Aventis, Eli Lilly, Biocon, Julphar, Exir, Sedico, Julphar, and Wockhardt

Sanofi: Sanofi, is one of the key competitors of the Global Basal Insulin (Long-Acting Insulin) Market; for instance, In February 2018, Sanofi Aventis had announced the launch of Toujeo, in India for the treatment of type 1 and type 2 diabetes improves glycemic control in adults. Toujeo acts for more than 24 hours,

Eli Lilly:  Eli Lilly is a popular competitor in the Global Basal Insulin (Long-Acting Insulin) Market. In February 2020, Eli Lilly had announced the acquisition of Dermira; the deal was made for USD 1.1 billion. They are a medical device company. The acquisition was made by Eli Lilly to strengthen its product portfolio with moderate-to-severe atopic dermatitis

 Scope of the Report

By Product Type

  • Lantus
  • Toujeo
  • Insulin Glargine Biosimilars
  • Others

By Application

  • Type1 Diabetes
  • Type 2 Diabetes

By Region

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Key Reasons to Purchase this Report

  1. It provides a technological development map over time to understand the growth rate of the industry.
  2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
  3. It renders definite analysis for changing competitive dynamics.
  4. It builds a seven-year estimate based on how the market is predicted to grow.

Table of Content

Chapter 1           Overview And Scope

1.1             Market Vision

1.1.1          Market Definition

1.1.2          Market Scope

1.2             Market Segmentation

Chapter 2           Our Research Practice

2.1             Our Research Methodology

2.2             Data Triangulation

2.3             Data Sources

2.4             Assumptions for the study

2.5             Approach Adopted

Chapter 3           Executive Summary

3.1             Market Snapshot

3.2             Regional Snapshot

3.3             Segment Summary

Chapter 4           Covid-19 Impact Analysis

4.1             Overview

4.2             Prevalence analysis

4.3             Key Factor Impact Analysis

Chapter 5           Global Basal Insulin (Long-Acting Insulin) Market Forces

5.1             What’s Driving the Market

5.2             Porter’s Five Forces Analysis

5.2.1          Power of Suppliers

5.2.2          Threats From New Entrants

5.2.3          Power of Buyer

5.2.4          Threat From Substitute Product

5.2.5          Degree of Competition

Chapter 6           Global Basal Insulin (Long-Acting Insulin) Market -Industry Snapshots

6.1             Overview

6.1.1          Global Basal Insulin (Long-Acting Insulin) Market Value, 2019 – 2026, (US$ Bn)

6.2             Market Overview

6.2.1          Drivers Analysis

6.2.2          Restraint/Challenges analysis

6.2.3          Opportunity Analysis

6.3             Supply Chain/Value Chain Analysis

6.4             Market SWOT Analysis

Chapter 7           Global Basal Insulin (Long-Acting Insulin) Market Analysis, by Product Type

7.1             Overview

7.2             Key Findings for Basal Insulin (Long-Acting Insulin) Market- By Product Type

7.2.1          Basal Insulin (Long-Acting Insulin) Market- Lantus

7.2.2          Basal Insulin (Long-Acting Insulin) Market- Toujeo

7.2.3          Basal Insulin (Long-Acting Insulin) Market- Insulin Glargine Biosimilars

7.2.4          Basal Insulin (Long-Acting Insulin) Market- Others

Chapter 8           Global Basal Insulin (Long-Acting Insulin) Market Analysis, by Application

8.1             Overview

8.2             Key Findings for Basal Insulin (Long-Acting Insulin) Market- By Application

8.2.1          Basal Insulin (Long-Acting Insulin) Market- Type1 Diabetes

8.2.2          Basal Insulin (Long-Acting Insulin) Market Type 2 Diabetes

Chapter 9           Basal Insulin (Long-Acting Insulin) Market Analysis by Region

9.1             Key Findings for Basal Insulin (Long-Acting Insulin) Market- By region

9.2             Overview

9.2.1          Global Basal Insulin (Long-Acting Insulin) Market Analysis, By Product Type, 2019 – 2026

9.2.2          Global Basal Insulin (Long-Acting Insulin) Market Analysis, By Application, 2019 – 2026

9.3             Basal Insulin (Long-Acting Insulin) Market – North America

9.3.1          Overview

9.3.2          U.S.

9.3.3          Canada

9.3.4          Mexico

9.3.5          North America Market, By Product Type

9.3.6          North America Market, By Application

9.4             Basal Insulin (Long-Acting Insulin) Market – Europe

9.4.1          Overview

9.4.2          Germany

9.4.3          United Kingdom

9.4.4          France

9.4.5          Italy

9.4.6          Rest Of Europe

9.4.7          Europe Market, By Product Type

9.4.8          Europe Market, By Application

9.5             Basal Insulin (Long-Acting Insulin) Market – Asia Pacific

9.5.1          Overview

9.5.2          China

9.5.3          Japan

9.5.4          India

9.5.5          Rest of APAC

9.5.6          Asia Pacific Market, By Product Type

9.5.7          Asia Pacific Market, By Application

9.6             Basal Insulin (Long-Acting Insulin) Market – LAMEA

9.6.1          Overview

9.6.2          Middle East & Africa (MEA)

9.6.3          Latin America

9.6.4          Rest Of World

9.6.5          Latin America, Middle East and Africa Market, By Product Type

9.6.6          Latin America, Middle East and Africa Market, By Application

Chapter 10       Market Competition Analysis

10.1           Market Share/Positioning Analysis

10.1.1       Market Positioning of Key Vendors, 2019

10.1.2       Key Strategies Adopted by the Leading Players

10.1.3       Recent Developments

Chapter 11       Company Profiles- Snapshot

11.1           Novo Nordisk

11.1.1       Business Fundamentals

11.1.2       Financial Snapshots

11.1.3       Product Portfolio

11.1.4       Recent Developments

11.2           Sanofi Aventis

11.3           Eli Lilly

11.4           Biocon

11.5           Julphar

11.6           Exir

11.7           Sedico

11.8           Julphar

11.9           Wockhardt

*More than 10 Companies are profiled in this Research Report*

*Financials would be provided on a best efforts basis for private companies”

Chapter 12       Appendix

 

 

 

Request for Sample

Please fill out the form to receive sample pages of the report